# US 2026/0062444 A1 · Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062444 A1
- Document ID: US20260062444A1
- Status: Published application
- Kind: A1
- Application number: 19/388,100
- Filed: 2025-11-13
- Published: 2026-03-05
- Earliest claimed: 2018-09-10
- Assignees: Rein Therapeutics, Inc.
- Applicants: Rein Therapeutics, Inc.
- Inventors: Dale CHRISTENSEN; John J. KOLENG
- Web page: https://patentgrep.com/patent/US20260062444A1

## CPC

- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 7/06: having 5 to 11 amino acids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

## Claims

### Claim 1

A method of treating or preventing fibrosis in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising a peptide consisting of an amino acid sequence of Ac-aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 8).

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is formulated for oral, intravenous, intraarticular, parenteral, enteral, subcutaneous, intramuscular, topical, buccal, sublingual, intraocular, epidural, intracranial, or inhalational administration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is formulated as an aqueous solution.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered systemically or locally to diseased tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered by inhalation.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition is administered by a nebulizer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the pharmaceutical composition is administered using a vibrating mesh nebulizer, jet nebulizer, or an ultrasonic nebulizer.

### Claim 9 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition is administered by an inhaler.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition is administered by a metered dose inhaler.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered in a single dose.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered in multiple doses.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pharmaceutical composition is administered in multiple doses, and the dose is administered once per day, once every two days, once per week, once every two weeks, or once per month.

### Claim 14 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered at a dose between about 0.1 mg/kg to about 500 mg/kg.

### Claim 15 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered at a dose between about 1 mg/kg to about 50 mg/kg.

### Claim 16 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered at a dose between about 1 mg/kg to about 10 mg/kg.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method further comprises administering at least one additional therapeutic.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one additional therapeutic is a non-steroidal anti-inflammatory drug, steroid, disease-modifying antirheumatic drug, immunosuppressive, biologic response modifier, bronchodilator, or anti-fibrotic agent.

### Claim 19 (depends on 18)

The method of claim 18, wherein the anti-fibrotic agent is pirfenidone.

### Claim 20 (depends on 1)

The method of claim 1, wherein the fibrosis is kidney fibrosis, liver fibrosis, heart fibrosis, or pulmonary fibrosis.

### Claim 21 (depends on 1)

The method of claim 1, wherein the fibrosis is pulmonary fibrosis.

### Claim 22 (depends on 1)

The method of claim 1, wherein the fibrosis is idiopathic pulmonary fibrosis.

### Claim 23 (depends on 1)

The method of claim 1, wherein the fibrosis results from acute or chronic lung injury.

### Claim 24 (depends on 1)

The method of claim 1, wherein the fibrosis is cystic fibrosis.

### Claim 25 (depends on 1)

The method of claim 1, wherein administration of the pharmaceutical composition increases viability of epithelial cells in the subject.

### Claim 26 (depends on 25)

The method of claim 25, wherein administration of the pharmaceutical composition increases viability of lung epithelial cells in the subject.

### Claim 27 (depends on 1)

The method of claim 1, wherein administration of the pharmaceutical composition modulates expression of smooth muscle actin in the subject.
